

=> file .biotech

=> s (activated protein C or aPC)

L1 24614 (ACTIVATED PROTEIN C OR APC)

=> s l1 and (aqueous solut?)

L2 350 L1 AND (AQUEOUS SOLUT?)

=> s l2 and (freeze-dried or cryoganul? or lyophiliz?)

L3 177 L2 AND (FREEZE-DRIED OR CRYOGANUL? OR LYOPHILIZ?)

=> s l3 and (liquid nitrogen)

L4 11 L3 AND (LIQUID NITROGEN)

=> s l4 and (bulking agent or sucrose)

L5 3 L4 AND (BULKING AGENT OR SUCROSE)

=> d l4 1-11 bib ab

L4 ANSWER 1 OF 11 USPATFULL

AN 1998:150739 USPATFULL

TI Alphavirus vector constructs

IN Dubensky, Jr., Thomas W., Rancho Sante Fe, CA, United States

Polo, John M., San Diego, CA, United States

Ibanez, Carlos E., San Diego, CA, United States

Chang, Stephen M. W., San Diego, CA, United States

Jolly, Douglas J., Leucadia, CA, United States

Driver, David A., San Diego, CA, United States

Belli, Barbara A., San Diego, CA, United States

PA Chiron Corporation, Emeryville, CA, United States (U.S. corporation)

PI US 5843723 19981201

AI US 1996-739167 19961030 (8)

RLI Continuation of Ser. No. US 1995-404796, filed on 20 Mar 1995 which is
a

continuation-in-part of Ser. No. US 1995-376184, filed on 20 Jan 1995,
now abandoned which is a continuation-in-part of Ser. No. US
1994-348472, filed on 30 Nov 1994, now abandoned which is a
continuation-in-part of Ser. No. US 1994-198450, filed on 18 Feb 1994,
now abandoned which is a continuation-in-part of Ser. No. US
1993-122791, filed on 15 Sep 1993, now abandoned

DT Utility

EXNAM Primary Examiner: Ketter, James; Assistant Examiner: Brusca, John S.

LREP McMasters, David D.; Kruse, Norman J.; Blackburn, Robert P.

CLMN Number of Claims: 47

ECL Exemplary Claim: 1

DRWN 37 Drawing Figure(s); 30 Drawing Page(s)

LN.CNT 10318

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions and method,, for utilizing
recombinant alphavirus vectors.

L4 ANSWER 2 OF 11 USPATFULL

AN 1998:144079 USPATFULL

TI Agents affecting thrombosis and hemostasis
 IN Wolf, David L., Palo Alto, CA, United States
 Sinha, Uma, San Francisco, CA, United States
 PA COR Therapeutics, Inc., South San Francisco, CA, United States (U.S.
 corporation)
 PI US 5837679 19981117
 AI US 1995-469301 19950606 (8)
 RLI Division of Ser. No. US 1994-268003, filed on 29 Jun 1994, now
 patented,
 Pat. No. US 5583107 which is a continuation-in-part of Ser. No. US
 1994-249777, filed on 26 May 1994, now patented, Pat. No. US 5597799
 which is a continuation of Ser. No. US 19 -808329 which is a
 continuation-in-part of Ser. No. US 1990-578646, filed on 4 Sep 1990,
 now patented, Pat. No. US 5278144
 DT Utility
 EXNAM Primary Examiner: Fleisher, Mindy; Assistant Examiner: Degen, Nancy J.
 LREP Morrison & Foerster LLP
 CLMN Number of Claims: 46
 ECL Exemplary Claim: 1
 DRWN 23 Drawing Figure(s); 15 Drawing Page(s)
 LN.CNT 2092
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Analogs of blood factors which are transiently inactive are useful in
 treatment of diseases characterized by thrombosis. In addition,
 modified
 forms of activated blood factors that generate the active blood factor
 in serum but have extended half-lives are useful in treating hemophilic
 conditions. These modified forms of the blood factor may be acylated
 forms which are slowly deacylated in vivo.

L4 ANSWER 3 OF 11 USPATFULL
 AN 1998:119004 USPATFULL
 TI Eukaryotic layered vector initiation systems
 IN Dubensky, Jr., Thomas W., P.O. Box 675205, Rancho Sante Fe, CA, United
 States 92067
 Polo, John M., 1222 Reed Ave., Number 4, San Diego, CA, United States
 92109
 Jolly, Douglas J., 277 Hillcrest Dr., Leucadia, CA, United States
 92024
 Driver, David A., 5142 Biltmore St., San Diego, CA, United States
 92117
 PI US 5814482 19980929
 AI US 1996-739158 19961030 (8)
 RLI Division of Ser. No. US 1995-404796, filed on 15 Mar 1995 which is a
 continuation-in-part of Ser. No. US 1995-376184, filed on 18 Jan 1995,
 now abandoned which is a continuation-in-part of Ser. No. US
 1994-348472, filed on 30 Nov 1994, now abandoned which is a
 continuation-in-part of Ser. No. US 1994-198450, filed on 18 Feb 1994,
 now abandoned which is a continuation-in-part of Ser. No. US
 1993-122791, filed on 15 Sep 1993, now abandoned
 DT Utility
 EXNAM Primary Examiner: Ketter, James; Assistant Examiner: Brusca, John S.
 LREP Seed & Berry; Kruse, Norman J.; Blackburn, Robert P.
 CLMN Number of Claims: 25
 ECL Exemplary Claim: 1
 DRWN 37 Drawing Figure(s); 30 Drawing Page(s)
 LN.CNT 10431
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention provides compositions and methods for utilizing
 recombinant alphavirus vectors. Also disclosed are compositions and

methods for making and utilizing eukaryotic layered vector initiation systems.

L4 ANSWER 4 OF 11 USPATFULL
AN 1998:91872 USPATFULL
TI Alphavirus structural protein expression cassettes
IN Dubensky, Jr., Thomas W., Rancho Sante Fe, CA, United States
Polo, John M., San Diego, CA, United States
Ibanez, Carlos E., San Diego, CA, United States
Chang, Stephen M. W., San Diego, CA, United States
Jolly, Douglas J., Leucadia, CA, United States
Driver, David A., San Diego, CA, United States
PA Chiron Corporation, Emeryville, CA, United States (U.S. corporation)
PI US 5789245 19980804
AI US 1996-741881 19961030 (8)
RLI Division of Ser. No. US 1995-404796, filed on 15 Mar 1995 which is a continuation-in-part of Ser. No. US 1995-376184, filed on 20 Jan 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-348472, filed on 30 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-198450, filed on 18 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-122791, filed on 15 Sep 1993, now abandoned
DT Utility
EXNAM Primary Examiner: Ketter, James; Assistant Examiner: Brusca, John S.
LREP McMasters, David D.; Kruse, Norman J.; Blackburn, Robert P.
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 35 Drawing Figure(s); 30 Drawing Page(s)
LN.CNT 10270

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems.

L4 ANSWER 5 OF 11 USPATFULL
AN 1998:85942 USPATFULL
TI Microparticles for delivery of nucleic acid
IN Hedley, Mary Lynne, Belmont, MA, United States
Curley, Joanne M., San Mateo, CA, United States
Langer, Robert S., Newton, MA, United States
PA Pangaea Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 5783567 19980721
AI US 1997-787547 19970122 (8)
DT Utility
EXNAM Primary Examiner: Degen, Nancy; Assistant Examiner: Brusca, John S.
LREP Fish & Richardson P.C.
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN 13 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 1732

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed is a preparation of microparticles made up of a polymeric matrix and a nucleic acid expression vector. The polymeric matrix includes one or more synthetic polymers having a solubility in water of less than about 1 mg/l. At least 90% of the microparticles have a diameter less than about 100 microns. The nucleic acid is either RNA,
at least 50% of which is in the form of closed circles, or circular DNA

plasmid molecules, at least 50% of which are supercoiled.

L4 ANSWER 6 OF 11 USPATFULL
AN 1998:51478 USPATFULL
TI DNA encoding MAGE-1 C-terminal cytotoxic t lymphocyte immunogenic peptides
IN Fikes, John D., San Diego, CA, United States
Livingston, Brian D., San Diego, CA, United States
Sette, Alessandro D., La Jolla, CA, United States
Sidney, John C., La Jolla, CA, United States
PA Cytel Corporation, San Diego, CA, United States (U.S. corporation)
PI US 5750395 19980512
AI US 1995-465167 19950605 (8)
RLI Division of Ser. No. US 1993-103623, filed on 6 Aug 1993, now abandoned
DT Utility
EXNAM Primary Examiner: Caputa, Anthony C.
LREP Townsend and Townsend and Crew
CLMN Number of Claims: 3
ECL Exemplary Claim: 2
DRWN 9 Drawing Figure(s); 8 Drawing Page(s)
LN.CNT 1512
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The complete nucleotide and amino acid sequences of the human MAGE-1 antigen are provided. Peptides from residues of the C-terminal are used to define epitopes that stimulate HLA-restricted cytotoxic T lymphocyte activity against MAGE-1 antigens. The peptides are particularly useful in methods for stimulating the immune response of individuals against MAGE-1 antigens associated with melanomas.

L4 ANSWER 7 OF 11 USPATFULL
AN 97:86587 USPATFULL
TI .alpha.-ketoamide derivatives as inhibitors of thrombosis
IN Abelman, Matthew M., Solana Beach, CA, United States
Pearson, Daniel A., Bedford, NH, United States
Vlasuk, George P., Carlsbad, CA, United States
Webb, Thomas R., Encinitas, CA, United States
PA Corvas International, Inc., San Diego, CA, United States (U.S. corporation)
PI US 5670479 19970923
AI US 1994-218329 19940325 (8)
RLI Continuation-in-part of Ser. No. US 1993-37574, filed on 25 Mar 1993
DT Utility
EXNAM Primary Examiner: Scheiner, Toni R.; Assistant Examiner: Huff, Sheela J.
LREP Lyon & Lyon LLP
CLMN Number of Claims: 60
ECL Exemplary Claim: 1
DRWN 13 Drawing Figure(s); 10 Drawing Page(s)
LN.CNT 4649
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB a-Ketoamide derivatives, their pharmaceutically acceptable salts, compositions, diagnostic compositions and pharmaceutical compositions, which are useful for preventing or treating in a mammal a pathological condition characterized by thrombosis are described.

a-Ketoamide derivatives, their pharmaceutically acceptable salts, compositions and diagnostic compositions, which are useful for in vivo imaging of thrombi in a mammal are also described.

Methods of preventing or treating in a mammal a pathological condition

characterized by thrombosis and methods of in vivo imaging of thrombi
in
a mammal are also disclosed.

L4 ANSWER 8 OF 11 USPATFULL
AN 97:71036 USPATFULL
TI .alpha.-ketoamide derivatives as inhibitors of thrombosis
IN Abelman, Matthew M., Solana Beach, CA, United States
Pearson, Daniel A., Solana Beach, CA, United States
Vlasuk, George P., Carlsbad, CA, United States
Webb, Thomas R., Encinitas, CA, United States
PA Corvas International, Inc., San Diego, CA, United States (U.S.
corporation)
PI US 5656600 19970812
AI US 1993-37574 19930325 (8)
DT Utility
EXNAM Primary Examiner: Scheiner, Toni R.; Assistant Examiner: Huff, Sheela
J.
LREP Lyon & Lyon LLP
CLMN Number of Claims: 81
ECL Exemplary Claim: 1
DRWN 5 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 4360
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB .alpha.-Ketoamide derivatives, their pharmaceutically acceptable salts,
compositions, diagnostic compositions and pharmaceutical compositions,
which are useful for preventing or treating in a mammal a pathological
condition characterized by thrombosis are described.

.alpha.-Ketoamide derivatives, their pharmaceutically acceptable salts,
compositions and diagnostic compositions, which are useful for in vivo
imaging of thrombi in a mammal are also described.

Methods of preventing or treating in a mammal a pathological condition
characterized by thrombosis and methods of in vivo imaging of thrombi
in
a mammal are also disclosed.

L4 ANSWER 9 OF 11 USPATFULL
AN 96:113902 USPATFULL
TI Agents affecting thrombosis and hemostasis
IN Wolf, David L., Palo Alto, CA, United States
Sinha, Uma, San Francisco, CA, United States
PA COR Therapeutics, Inc., South San Francisco, CA, United States (U.S.
corporation)
PI US 5583107 19961210
AI US 1994-268003 19940629 (8)
RLI Continuation-in-part of Ser. No. US 1994-249777, filed on 26 May 1994
which is a continuation of Ser. No. US 1991-808329, filed on 16 Dec
1991, now abandoned which is a continuation-in-part of Ser. No. US
1990-578646, filed on 4 Sep 1990, now patented, Pat. No. US 5278144
DT Utility
EXNAM Primary Examiner: Elliott, George C.; Assistant Examiner: Degen, Nancy
J.
LREP Morrison & Foerster LLP
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 23 Drawing Figure(s); 15 Drawing Page(s)
LN.CNT 1955
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Analogs of blood factors which are transiently inactive are useful in treatment of diseases characterized by thrombosis. In addition, modified forms of activated blood factors that generate the active blood factor in serum but have extended half-lives are useful in treating hemophilic conditions. These modified forms of the blood factor may be acylated forms which are slowly deacylated in vivo.

L4 ANSWER 10 OF 11 USPATFULL
AN 94:15636 USPATFULL
TI Assay methods for detecting serum proteases, particularly **activated protein C**
IN Griffin, John H., Del Mar, CA, United States
 Gruber, Andras, San Diego, CA, United States
PA The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation)
PI US 5288612 19940222
AI US 1991-725359 19910703 (7)
DT Utility
EXNAM Primary Examiner: Griffin, Ronald W.; Assistant Examiner: Webber, Pamela
 S.

LREP Bingham, Douglas A.; Fitting, Thomas; Logan, April C.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 5 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 1792

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention describes diagnostic methods and compositions for determining the amount of protease in a body fluid sample. In particular, the invention detects proteases by a method in which both a reversible inhibitor of the protease and an irreversible inhibitor of interfering proteases during the detection step are employed to increase the sensitivity of the enzyme capture assay. The assay detects normal serum levels of **activated protein C**.

L4 ANSWER 11 OF 11 USPATFULL
AN 93:12427 USPATFULL
TI Immunological determination of free human protein S and C4bp-protein S complex
IN Koike, Yukiya, Hino, Japan
 Wakabayashi, Kenji, Hino, Japan
 Sumi, Yoshihiko, Hino, Japan
 Ichikawa, Yataro, Tokorozawa, Japan
PA Teijin Limited, Osaka, Japan (non-U.S. corporation)
PI US 5187067 19930216
AI US 1991-670383 19910314 (7)
RLI Continuation of Ser. No. US 1987-132886, filed on 9 Dec 1987, now abandoned
PRAI JP 1986-296766 19861215
 JP 1986-298881 19861217
DT Utility
EXNAM Primary Examiner: Lacey, David L.; Assistant Examiner: Feisee, Lila
LREP Wenderoth, Lind & Ponack
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 886
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of immunologically determining free human protein S in an assay sample, which comprises contacting a primary antibody fixed to an insoluble solid carrier and a labelled secondary antibody with the assay sample, the primary and secondary antibodies having the property of binding to different epitopes of free human protein S, and one of the primary and secondary antibodies being a monoclonal antibody having the property of not binding to a complex of the human protein S and human complement cofactor C4b-binding protein (C4bp) but specifically binding to the free human protein S. Also provided is a method of immunologically determining a complex of human protein S and human complement cofactor C4b-binding protein (C4bp) in an assay sample, which comprises contacting a primary antibody fixed to an insoluble solid carrier and a labelled secondary antibody with the assay sample, one of the primary and secondary antibodies being a monoclonal antibody having the property of not binding to free human protein S and human complement cofactor C4b-binding protein (C4bp) but binding specifically to the complex, and the other being an antibody having the property of binding to the human complement cofactor C4b-binding protein (C4bp).

=> d 15 1-3 bib ab

L5 ANSWER 1 OF 3 USPATFULL
AN 1998:150739 USPATFULL
TI Alphavirus vector constructs
IN Dubensky, Jr., Thomas W., Rancho Sante Fe, CA, United States
Polo, John M., San Diego, CA, United States
Ibanez, Carlos E., San Diego, CA, United States
Chang, Stephen M. W., San Diego, CA, United States
Jolly, Douglas J., Leucadia, CA, United States
Driver, David A., San Diego, CA, United States
Belli, Barbara A., San Diego, CA, United States
PA Chiron Corporation, Emeryville, CA, United States (U.S. corporation)
PI US 5843723 19981201
AI US 1996-739167 19961030 (8)
RLI Continuation of Ser. No. US 1995-404796, filed on 20 Mar 1995 which is
a continuation-in-part of Ser. No. US 1995-376184, filed on 20 Jan 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-348472, filed on 30 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-198450, filed on 18 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-122791, filed on 15 Sep 1993, now abandoned
DT Utility
EXNAM Primary Examiner: Ketter, James; Assistant Examiner: Brusca, John S.
LREP McMasters, David D.; Kruse, Norman J.; Blackburn, Robert P.
CLMN Number of Claims: 47
ECL Exemplary Claim: 1
DRWN 37 Drawing Figure(s); 30 Drawing Page(s)
LN.CNT 10318
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides compositions and method,, for utilizing recombinant alphavirus vectors.

L5 ANSWER 2 OF 3 USPATFULL
AN 1998:119004 USPATFULL

TI Eukaryotic layered vector initiation systems
 IN Dubensky, Jr., Thomas W., P.O. Box 675205, Rancho Sante Fe, CA, United States 92067
 Polo, John M., 1222 Reed Ave., Number 4, San Diego, CA, United States 92109
 Jolly, Douglas J., 277 Hillcrest Dr., Leucadia, CA, United States 92024
 Driver, David A., 5142 Biltmore St., San Diego, CA, United States 92117
 PI US 5814482 19980929
 AI US 1996-739158 19961030 (8)
 RLI Division of Ser. No. US 1995-404796, filed on 15 Mar 1995 which is a continuation-in-part of Ser. No. US 1995-376184, filed on 18 Jan 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-348472, filed on 30 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-198450, filed on 18 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-122791, filed on 15 Sep 1993, now abandoned
 DT Utility
 EXNAM Primary Examiner: Ketter, James; Assistant Examiner: Brusca, John S.
 LREP Seed & Berry; Kruse, Norman J.; Blackburn, Robert P.
 CLMN Number of Claims: 25
 ECL Exemplary Claim: 1
 DRWN 37 Drawing Figure(s); 30 Drawing Page(s)
 LN.CNT 10431
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems.

 L5 ANSWER 3 OF 3 USPATFULL
 AN 1998:91872 USPATFULL
 TI Alphavirus structural protein expression cassettes
 IN Dubensky, Jr., Thomas W., Rancho Sante Fe, CA, United States
 Polo, John M., San Diego, CA, United States
 Ibanez, Carlos E., San Diego, CA, United States
 Chang, Stephen M. W., San Diego, CA, United States
 Jolly, Douglas J., Leucadia, CA, United States
 Driver, David A., San Diego, CA, United States
 PA Chiron Corporation, Emeryville, CA, United States (U.S. corporation)
 PI US 5789245 19980804
 AI US 1996-741881 19961030 (8)
 RLI Division of Ser. No. US 1995-404796, filed on 15 Mar 1995 which is a continuation-in-part of Ser. No. US 1995-376184, filed on 20 Jan 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-348472, filed on 30 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-198450, filed on 18 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-122791, filed on 15 Sep 1993, now abandoned
 DT Utility
 EXNAM Primary Examiner: Ketter, James; Assistant Examiner: Brusca, John S.
 LREP McMasters, David D.; Kruse, Norman J.; Blackburn, Robert P.
 CLMN Number of Claims: 29
 ECL Exemplary Claim: 1
 DRWN 35 Drawing Figure(s); 30 Drawing Page(s)
 LN.CNT 10270
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and

methods for making and utilizing eukaryotic layered vector initiation systems.

=> s activated protein C or aPC and (cryogranulat? or lyophiliz? or freez? or freeze-dry?)

L6 6601 ACTIVATED PROTEIN C OR APC AND (CRYOGRANULAT? OR LYOPHILIZ? OR FREEZ? OR FREEZE-DRY?)

=> s l6 and (liquid nitrogen)

L7 41 L6 AND (LIQUID NITROGEN)

=> s l7 and (bulking agent or sucrose)

L8 7 L7 AND (BULKING AGENT OR SUCROSE)

=> d l8 1-7 bib ab

L8 ANSWER 1 OF 7 USPATFULL

AN 1998:150739 USPATFULL

TI Alphavirus vector constructs

IN Dubensky, Jr., Thomas W., Rancho Sante Fe, CA, United States

Polo, John M., San Diego, CA, United States

Ibanez, Carlos E., San Diego, CA, United States

Chang, Stephen M. W., San Diego, CA, United States

Jolly, Douglas J., Leucadia, CA, United States

Driver, David A., San Diego, CA, United States

Belli, Barbara A., San Diego, CA, United States

PA Chiron Corporation, Emeryville, CA, United States (U.S. corporation)

PI US 5843723 19981201

AI US 1996-739167 19961030 (8)

RLI Continuation of Ser. No. US 1995-404796, filed on 20 Mar 1995 which is
a

continuation-in-part of Ser. No. US 1995-376184, filed on 20 Jan 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-348472, filed on 30 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-198450, filed on 18 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-122791, filed on 15 Sep 1993, now abandoned

DT Utility

EXNAM Primary Examiner: Ketter, James; Assistant Examiner: Brusca, John S.

LREP McMasters, David D.; Kruse, Norman J.; Blackburn, Robert P.

CLMN Number of Claims: 47

ECL Exemplary Claim: 1

DRWN 37 Drawing Figure(s); 30 Drawing Page(s)

LN.CNT 10318

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions and method,, for utilizing recombinant alphavirus vectors.

L8 ANSWER 2 OF 7 USPATFULL

AN 1998:143883 USPATFULL

TI Method of identifying modulators of binding between and VCAM-1

IN Gallatin, W. Michael, Mercer Island, WA, United States

Van der Vieren, Monica, Seattle, WA, United States

PA ICOS Corporation, Bothell, WA, United States (U.S. corporation)

PI US 5837478 19981117

AI US 1997-943363 19971003 (8)

RLI Continuation-in-part of Ser. No. US 1996-605672, filed on 22 Feb 1996 which is a continuation-in-part of Ser. No. US 1994-362652, filed on 21 Dec 1994, now patented, Pat. No. US 5766850 which is a continuation-in-part of Ser. No. US 1994-286889, filed on 5 Aug 1994, now patented, Pat. No. US 5470953, issued on 28 Nov 1995 which is a continuation-in-part of Ser. No. US 1993-173497, filed on 23 Dec 1993, now patented, Pat. No. US 5437958, issued on 1 Aug 1995

DT Utility

EXNAM Primary Examiner: Feisee, Lila; Assistant Examiner: Gambel, Phillip

LREP Marshall, O'Toole, Gerstein, Murray & Borun

CLMN Number of Claims: 4

ECL Exemplary Claim: 1

DRWN 5 Drawing Figure(s); 4 Drawing Page(s)

LN.CNT 7878

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods to identify modulators of .alpha..sub.d binding to VCAM-1 are disclosed.

L8 ANSWER 3 OF 7 USPATFULL

AN 1998:119004 USPATFULL

TI Eukaryotic layered vector initiation systems

IN Dubensky, Jr., Thomas W., P.O. Box 675205, Rancho Sante Fe, CA, United States 92067

Polo, John M., 1222 Reed Ave., Number 4, San Diego, CA, United States 92109

Jolly, Douglas J., 277 Hillcrest Dr., Leucadia, CA, United States

92024 Driver, David A., 5142 Biltmore St., San Diego, CA, United States

92117

PI US 5814482 19980929

AI US 1996-739158 19961030 (8)

RLI Division of Ser. No. US 1995-404796, filed on 15 Mar 1995 which is a continuation-in-part of Ser. No. US 1995-376184, filed on 18 Jan 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-348472, filed on 30 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-198450, filed on 18 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-122791, filed on 15 Sep 1993, now abandoned

DT Utility

EXNAM Primary Examiner: Ketter, James; Assistant Examiner: Brusca, John S.

LREP Seed & Berry; Kruse, Norman J.; Blackburn, Robert P.

CLMN Number of Claims: 25

ECL Exemplary Claim: 1

DRWN 37 Drawing Figure(s); 30 Drawing Page(s)

LN.CNT 10431

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems.

L8 ANSWER 4 OF 7 USPATFULL

AN 1998:91872 USPATFULL

TI Alphavirus structural protein expression cassettes

IN Dubensky, Jr., Thomas W., Rancho Sante Fe, CA, United States

Polo, John M., San Diego, CA, United States

Ibanez, Carlos E., San Diego, CA, United States

Chang, Stephen M. W., San Diego, CA, United States

Jolly, Douglas J., Leucadia, CA, United States

Driver, David A., San Diego, CA, United States

PA Chiron Corporation, Emeryville, CA, United States (U.S. corporation)
PI US 5789245 19980804
AI US 1996-741881 19961030 (8)
RLI Division of Ser. No. US 1995-404796, filed on 15 Mar 1995 which is a continuation-in-part of Ser. No. US 1995-376184, filed on 20 Jan 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-348472, filed on 30 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-198450, filed on 18 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-122791, filed on 15 Sep 1993, now abandoned
DT Utility
EXNAM Primary Examiner: Ketter, James; Assistant Examiner: Brusca, John S.
LREP McMasters, David D.; Kruse, Norman J.; Blackburn, Robert P.
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 35 Drawing Figure(s); 30 Drawing Page(s)
LN.CNT 10270

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems.

L8 ANSWER 5 OF 7 USPATFULL
AN 1998:91599 USPATFULL
TI Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
IN Murphy, Gerald P., Seattle, WA, United States
Boynton, Alton L., Redmond, WA, United States
Tjoa, Benjamin A., Seattle, WA, United States
PA Pacific Northwest Cancer Foundation, Seattle, WA, United States (U.S. corporation)
PI US 5788963 19980804
AI US 1995-509254 19950731 (8)
DT Utility
EXNAM Primary Examiner: Scheiner, Toni R.
LREP Pennie & Edmonds LLP
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 9 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 1348

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and compositions for use of human dendritic cells to activate T cells for immunotherapeutic responses against primary and metastatic prostate cancer are disclosed. In one embodiment, human dendritic cells,

after exposure to a prostate cancer antigen or specific antigenic peptide, are administered to a prostate cancer patient to activate the relevant T cell responses in vivo. In an alternate embodiment, human dendritic cells are exposed to a prostate cancer antigen or specific antigenic peptide in vitro and incubated or cultured with primed or unprimed T cells to activate the relevant T cell responses in vitro.

The activated T cells are then administered to a prostate cancer patient. Methods and compositions for human dendritic cells with extended life span and cryopreserved dendritic cells are disclosed.

L8 ANSWER 6 OF 7 USPATFULL
AN 1998:27773 USPATFULL
TI Method of cancer treatment

IN Terman, David S., P.O. Box 987, Pebble Beach, CA, United States 93953
PI US 5728388 19980317
AI US 1994-189424 19940131 (8)
RLI Continuation-in-part of Ser. No. US 1993-25144, filed on 2 Mar 1993,
now

abandoned And Ser. No. US 1992-891718, filed on 1 Jun 1992, now
abandoned which is a continuation-in-part of Ser. No. US 1990-466577,
filed on 17 Jan 1990, now abandoned which is a continuation-in-part of
Ser. No. US 1989-416530, filed on 3 Oct 1989, now abandoned

DT Utility
EXNAM Primary Examiner: Schwartz, Richard A.; Assistant Examiner: Cech, Emma
LREP Skjerven, Morrill, MacPherson, Franklin & Friel LLP; Terlizzi, Laura;
Haliday, Emily M.
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN 4 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 1515

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Treatment of solid tumors, including their metastases, without
radiation, surgery or standard chemotherapeutic agents is described. Ex
vivo stimulation of cells, selection of specific V.beta. subsets of
stimulated cells and reinfusion of the V.beta. subsets of stimulated
cells is employed for cancer therapy.

L8 ANSWER 7 OF 7 USPATFULL

AN 97:22652 USPATFULL

TI Ascorbate oxidase, gene encoding the same, process for producing the
same, and reagent composition using the same

IN Nakanishi, Yuji, Aichi, Japan
Amano, Hitoshi, Ibaraki, Japan
Yamaguchi, Shotaro, Ibaraki, Japan

PA Amano Pharmaceutical Co., Ltd., Aichi, Japan (non-U.S. corporation)

PI US 5612208 19970318

AI US 1995-439114 19950511 (8)

PRAI JP 1994-123113 19940511

DT Utility

EXNAM Primary Examiner: Jacobson, Dian C.; Assistant Examiner: Nashed,
Nashaat

T.

LREP Sughrue, Mion, Zinn, Macpeak & Seas

CLMN Number of Claims: 11

ECL Exemplary Claim: 1

DRWN 14 Drawing Figure(s); 13 Drawing Page(s)

LN.CNT 1597

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a novel ascorbate oxidase (ASOD) which
catalyzes oxidation reaction of L-ascorbic acid with molecular oxygen
to

form L-dehydroascorbic acid and hydrogen peroxide, a process for
producing the ascorbate oxidase comprising using a microorganism
belonging to the genus Eupenicillium, a gene encoding ASOD, a
transformant containing such a gene, a process for producing ASOD using
such a transformant, and a reagent composition comprising ASOD, such as
a reagent composition for examination, a food additive, and a reagent
composition in the fields of food and clinical examination. The
ascorbate oxidase has excellent stability particularly in a liquid
state.

=> s cryogranulation and (activated protein C or aPC)

L9 0 CRYOGRANULATION AND (ACTIVATED PROTEIN C OR APC)

=> s crygranult? and (activated protein C or aPC)

L10 0 CRYGRANULT? AND (ACTIVATED PROTEIN C OR APC)

=> s freez? and (activated protein C oe aPC)

L11 0 FREEZ? AND (ACTIVATED PROTEIN C OE APC)

=> s lyophiliz? and (activated protein C or aPC)

L12 321 LYOPHILIZ? AND (ACTIVATED PROTEIN C OR APC)

=> s 112 and (sucrose)

L13 83 L12 AND (SUCROSE)

=> s 113 and (liquid nitrogen)

L14 6 L13 AND (LIQUID NITROGEN)

=> d 114 1-6 bib ab

L14 ANSWER 1 OF 6 USPATFULL

AN 1998:150739 USPATFULL

TI Alphavirus vector constructs

IN Dubensky, Jr., Thomas W., Rancho Sante Fe, CA, United States

Polo, John M., San Diego, CA, United States

Ibanez, Carlos E., San Diego, CA, United States

Chang, Stephen M. W., San Diego, CA, United States

Jolly, Douglas J., Leucadia, CA, United States

Driver, David A., San Diego, CA, United States

Belli, Barbara A., San Diego, CA, United States

PA Chiron Corporation, Emeryville, CA, United States (U.S. corporation)

PI US 5843723 19981201

AI US 1996-739167 19961030 (8)

RLI Continuation of Ser. No. US 1995-404796, filed on 20 Mar 1995 which is

a

continuation-in-part of Ser. No. US 1995-376184, filed on 20 Jan 1995,

now abandoned which is a continuation-in-part of Ser. No. US

1994-348472, filed on 30 Nov 1994, now abandoned which is a

continuation-in-part of Ser. No. US 1994-198450, filed on 18 Feb 1994,

now abandoned which is a continuation-in-part of Ser. No. US

1993-122791, filed on 15 Sep 1993, now abandoned

DT Utility

EXNAM Primary Examiner: Ketter, James; Assistant Examiner: Brusca, John S.

LREP McMasters, David D.; Kruse, Norman J.; Blackburn, Robert P.

CLMN Number of Claims: 47

ECL Exemplary Claim: 1

DRWN 37 Drawing Figure(s); 30 Drawing Page(s)

LN.CNT 10318

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions and method,, for utilizing recombinant alphavirus vectors.

L14 ANSWER 2 OF 6 USPATFULL

AN 1998:143883 USPATFULL

TI Method of identifying modulators of binding between and VCAM-1

IN Gallatin, W. Michael, Mercer Island, WA, United States
Van der Vieren, Monica, Seattle, WA, United States
PA ICOS Corporation, Bothell, WA, United States (U.S. corporation)
PI US 5837478 19981117
AI US 1997-943363 19971003 (8)
RLI Continuation-in-part of Ser. No. US 1996-605672, filed on 22 Feb 1996
which is a continuation-in-part of Ser. No. US 1994-362652, filed on 21
Dec 1994, now patented, Pat. No. US 5766850 which is a
continuation-in-part of Ser. No. US 1994-286889, filed on 5 Aug 1994,
now patented, Pat. No. US 5470953, issued on 28 Nov 1995 which is a
continuation-in-part of Ser. No. US 1993-173497, filed on 23 Dec 1993,
now patented, Pat. No. US 5437958, issued on 1 Aug 1995
DT Utility
EXNAM Primary Examiner: Feisee, Lila; Assistant Examiner: Gambel, Phillip
LREP Marshall, O'Toole, Gerstein, Murray & Borun
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN 5 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 7878
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods to identify modulators of .alpha..sub.d binding to VCAM-1 are
disclosed.

L14 ANSWER 3 OF 6 USPATFULL
AN 1998:119004 USPATFULL
TI Eukaryotic layered vector initiation systems
IN Dubensky, Jr., Thomas W., P.O. Box 675205, Rancho Sante Fe, CA, United
States 92067
Polo, John M., 1222 Reed Ave., Number 4, San Diego, CA, United States
92109
Jolly, Douglas J., 277 Hillcrest Dr., Leucadia, CA, United States
92024 Driver, David A., 5142 Biltmore St., San Diego, CA, United States
92117
PI US 5814482 19980929
AI US 1996-739158 19961030 (8)
RLI Division of Ser. No. US 1995-404796, filed on 15 Mar 1995 which is a
continuation-in-part of Ser. No. US 1995-376184, filed on 18 Jan 1995,
now abandoned which is a continuation-in-part of Ser. No. US
1994-348472, filed on 30 Nov 1994, now abandoned which is a
continuation-in-part of Ser. No. US 1994-198450, filed on 18 Feb 1994,
now abandoned which is a continuation-in-part of Ser. No. US
1993-122791, filed on 15 Sep 1993, now abandoned
DT Utility
EXNAM Primary Examiner: Ketter, James; Assistant Examiner: Brusca, John S.
LREP Seed & Berry; Kruse, Norman J.; Blackburn, Robert P.
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN 37 Drawing Figure(s); 30 Drawing Page(s)
LN.CNT 10431
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides compositions and methods for utilizing
recombinant alphavirus vectors. Also disclosed are compositions and
methods for making and utilizing eukaryotic layered vector initiation
systems.

L14 ANSWER 4 OF 6 USPATFULL
AN 1998:91872 USPATFULL
TI Alphavirus structural protein expression cassettes
IN Dubensky, Jr., Thomas W., Rancho Sante Fe, CA, United States

Polo, John M., San Diego, CA, United States
 Ibanez, Carlos E., San Diego, CA, United States
 Chang, Stephen M. W., San Diego, CA, United States
 Jolly, Douglas J., Leucadia, CA, United States
 Driver, David A., San Diego, CA, United States
 PA Chiron Corporation, Emeryville, CA, United States (U.S. corporation)
 PI US 5789245 19980804
 AI US 1996-741881 19961030 (8)
 RLI Division of Ser. No. US 1995-404796, filed on 15 Mar 1995 which is a
 continuation-in-part of Ser. No. US 1995-376184, filed on 20 Jan 1995,
 now abandoned which is a continuation-in-part of Ser. No. US
 1994-348472, filed on 30 Nov 1994, now abandoned which is a
 continuation-in-part of Ser. No. US 1994-198450, filed on 18 Feb 1994,
 now abandoned which is a continuation-in-part of Ser. No. US
 1993-122791, filed on 15 Sep 1993, now abandoned
 DT Utility
 EXNAM Primary Examiner: Ketter, James; Assistant Examiner: Brusca, John S.
 LREP McMasters, David D.; Kruse, Norman J.; Blackburn, Robert P.
 CLMN Number of Claims: 29
 ECL Exemplary Claim: 1
 DRWN 35 Drawing Figure(s); 30 Drawing Page(s)
 LN.CNT 10270
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention provides compositions and methods for utilizing
 recombinant alphavirus vectors. Also disclosed are compositions and
 methods for making and utilizing eukaryotic layered vector initiation
 systems.
 L14 ANSWER 5 OF 6 USPATFULL
 AN 1998:27773 USPATFULL
 TI Method of cancer treatment
 IN Terman, David S., P.O. Box 987, Pebble Beach, CA, United States 93953
 PI US 5728388 19980317
 AI US 1994-189424 19940131 (8)
 RLI Continuation-in-part of Ser. No. US 1993-25144, filed on 2 Mar 1993,
 now
 abandoned And Ser. No. US 1992-891718, filed on 1 Jun 1992, now
 abandoned which is a continuation-in-part of Ser. No. US 1990-466577,
 filed on 17 Jan 1990, now abandoned which is a continuation-in-part of
 Ser. No. US 1989-416530, filed on 3 Oct 1989, now abandoned
 DT Utility
 EXNAM Primary Examiner: Schwartz, Richard A.; Assistant Examiner: Cech, Emma
 LREP Skjerven, Morrill, MacPherson, Franklin & Friel LLP; Terlizzi, Laura;
 Haliday, Emily M.
 CLMN Number of Claims: 32
 ECL Exemplary Claim: 1
 DRWN 4 Drawing Figure(s); 4 Drawing Page(s)
 LN.CNT 1515
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Treatment of solid tumors, including their metastases, without
 radiation, surgery or standard chemotherapeutic agents is described. Ex
 vivo stimulation of cells, selection of specific V.beta. subsets of
 stimulated cells and reinfusion of the V.beta. subsets of stimulated
 cells is employed for cancer therapy.
 L14 ANSWER 6 OF 6 USPATFULL
 AN 97:22652 USPATFULL
 TI Ascorbate oxidase, gene encoding the same, process for producing the
 same, and reagent composition using the same
 IN Nakanishi, Yuji, Aichi, Japan

Amano, Hitoshi, Ibaraki, Japan
Yamaguchi, Shotaro, Ibaraki, Japan
PA Amano Pharmaceutical Co., Ltd., Aichi, Japan (non-U.S. corporation)
PI US 5612208 19970318
AI US 1995-439114 19950511 (8)
PRAI JP 1994-123113 19940511
DT Utility
EXNAM Primary Examiner: Jacobson, Dian C.; Assistant Examiner: Nashed,
Nashaat

T.
LREP Sughrue, Mion, Zinn, Macpeak & Seas
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 14 Drawing Figure(s); 13 Drawing Page(s)
LN.CNT 1597

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a novel ascorbate oxidase (ASOD) which
catalyzes oxidation reaction of L-ascorbic acid with molecular oxygen
to

form L-dehydroascorbic acid and hydrogen peroxide, a process for
producing the ascorbate oxidase comprising using a microorganism
belonging to the genus Eupenicillium, a gene encoding ASOD, a
transformant containing such a gene, a process for producing ASOD using
such a transformant, and a reagent composition comprising ASOD, such as
a reagent composition for examination, a food additive, and a reagent
composition in the fields of food and clinical examination. The
ascorbate oxidase has excellent stability particularly in a liquid
state.

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

STN INTERNATIONAL LOGOFF AT 10:13:05 ON 03 SEP 1999